TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15498611

Group type: EXPERIMENTAL
Intervention: Certified mail
Number of subjects: 271

Group type: COMPARATOR
Intervention: Regular mail
Number of subjects: 271
Study: 11181472

Group type: EXPERIMENTAL
Intervention: Tezosentan 5 mg/h
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tezosentan 20 mg/h
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tezosentan 50 mg/h
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tezosentan 100 mg/h
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9886750

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Treatment with insulin or oral hypoglycaemic agents
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Greater height
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Lower 2-h plasma insulin
Number of subjects: 847
Study: 8299317

Group type: EXPERIMENTAL
Intervention: MK-0963 10 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MK-0963 25 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3175860

Group type: EXPERIMENTAL
Intervention: Early surgery (less than 48 hours after admission)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Delayed surgery (more than 48 hours after admission)
Number of subjects: 165
Study: 4923928

Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Amylobarbitone 150 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Inert substance
Number of subjects: 4
Study: 31166116

Group type: EXPERIMENTAL
Intervention: Barefoot habituation group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shod habituation group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 60
Study: 29276925

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 26193177

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 54

Group type: COMPARATOR
Intervention: IMT
Number of subjects: 54
Study: 23306963

Group type: EXPERIMENTAL
Intervention: Mirror image overlay guidance
Number of subjects: 113

Group type: COMPARATOR
Intervention: No guidance (Control)
Number of subjects: 113
Study: 21334389

Group type: EXPERIMENTAL
Intervention: Predictable shock timing and intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable shock timing and intensity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19804626

Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 493

Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 493
Study: 17269421

Group type: EXPERIMENTAL
Intervention: Essliver Forte
Number of subjects: 60
Study: 15039411

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Expanded medical treatment
Number of subjects: 63
Study: 10096642

Group type: EXPERIMENTAL
Intervention: Elevated EPQ score on the neuroticism subscale, short duration of treatment, slow onset of response to treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42
Study: 8677916

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (arm IV: i.a. and i.v. MMC + p.o. 5‐FU; arm V: i.v. MMC + p.o. 5‐FU) for rectal cancer
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (arm I: i.p. and i.v. MMC + p.o. 5‐FU; arm II: i.v. MMC + p.o. 5‐FU) for colonic cancer
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Surgery only (arm III for colonic cancer; arm VI for rectal cancer)
Number of subjects: 1254
Study: 1848618

Group type: EXPERIMENTAL
Intervention: Ganciclovir plus recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ganciclovir alone
Number of subjects: 36
Study: 6433099

Group type: EXPERIMENTAL
Intervention: Acetate hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro studies with uremic blood cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High urea dialysance treatments
Number of subjects: 0
Study: 30367258

Group type: EXPERIMENTAL
Intervention: Active PBMT (850 nm, 240 J per limb) before each training session
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment before each training session
Number of subjects: 24
Study: 28880050

Group type: EXPERIMENTAL
Intervention: Active patches
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham patches
Number of subjects: 30
Study: 25912232

Group type: EXPERIMENTAL
Intervention: MSF (50:40:10 MCT:SO:FO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MS (50:50 MCT:SO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MSF
Number of subjects: 40
Study: 25272070

Group type: EXPERIMENTAL
Intervention: Vibration Anesthesia Device (group 1, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Venipuncture only (group 2, n = 30)
Number of subjects: 60
Study: 22455413

Group type: EXPERIMENTAL
Intervention: 150 mg ixekizumab
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 75 mg ixekizumab
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 25 mg ixekizumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 21115906

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30
Study: 18182600

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus metformin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Metformin alone (750 mg/d)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus placebo
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 15684150

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) therapy
Number of subjects: 30000
Study: 12968983

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10952119

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin
Number of subjects: 0
Study: 8932976

Group type: EXPERIMENTAL
Intervention: 2 g supplemental calcium daily
Number of subjects: 4589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study: 2053000

Group type: EXPERIMENTAL
Intervention: Epidural injections of 80 mg triamcinolone acetonide plus 0.5% procaine hydrochloride in saline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6407500

Group type: COMPARATOR
Intervention: Amitriptyline (50 mg and 75 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Doxepin (50 mg and 75 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg, 75 mg and 100 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Doxepin (75 mg)
Number of subjects: 17
Study: 31806432

Group type: COMPARATOR
Intervention: fentanyl target‐controlled infusion (fTCI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 39
Study: 31320597

Group type: EXPERIMENTAL
Intervention: ICT‐107 (autologous dendritic cells pulsed with six synthetic peptide epitopes targeting GBM tumor/stem cell‐associated antigens)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ICT‐107
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (unpulsed DC)
Number of subjects: 124
Study: 29759604

Group type: EXPERIMENTAL
Intervention: IRSplus
Number of subjects: 230

Group type: COMPARATOR
Intervention: VpS
Number of subjects: 230
Study: 27030601

Group type: EXPERIMENTAL
Intervention: Prior clopidogrel
Number of subjects: 8927

Group type: COMPARATOR
Intervention: Clopidogrel in-hospital
Number of subjects: 8927

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 8927
Study: 25356046

Group type: EXPERIMENTAL
Intervention: pH capsule
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional catheter and pH capsule
Number of subjects: 91
Study: 23257033

Group type: EXPERIMENTAL
Intervention: Adrenaline (Ad) group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: PV group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: PV plus Ad group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: PIB group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ad group
Number of subjects: 155
Study: 20402816

Group type: EXPERIMENTAL
Intervention: 5-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID) and metronidazole (500 mg TID) for 9 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: 14-day amoxicillin (1 g BID) followed by tetracycline (500 mg QID), metronidazole (500 mg TID), and amoxicillin (1 g BID) for 9 days
Number of subjects: 112
Study: 18616522

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg x kg(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 16096454

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound (D)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Static ultrasound (S)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Anatomical landmarks (LM)
Number of subjects: 201
Study: 12433733

Group type: EXPERIMENTAL
Intervention: High pretreatment serum concentration of bFGF (S-bFGF >= 17 pg/ml)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Low pretreatment serum concentration of bFGF (S-bFGF < 17 pg/ml)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with extensive-stage disease and high S-bFGF (>= 17 pg/ml)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with extensive-stage disease
Number of subjects: 103
Study: 10341329

Group type: EXPERIMENTAL
Intervention: Candidate standard AA (lyophilised)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Candidate standard BB (lyophilised)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Candidate standard CC (liquid preparation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Various NAT assays (including Roche Amplicor, Chiron Quantiplex, Organon Teknika NASBA, and in-house assays)
Number of subjects: 22
Study: 8444211

Group type: EXPERIMENTAL
Intervention: Oral vitamin K supplementation at birth (n = 22)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) vitamin K supplementation at birth (n = 18)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Breastfed without supplementation (n = 25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Formula feeding (n = 15)
Number of subjects: 80
Study: 3021487

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade 4 mg q.i.d.)
Number of subjects: 51
Study: 27976591

Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy (HILT) with total energy of 1500 J through three phases/3 sessions/week for three consecutive months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo laser therapy with the same physical therapy programme
Number of subjects: 30
Study: 27179167

Group type: EXPERIMENTAL
Intervention: Combined treatment of RF and ultrasound cavitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low calorie diet alone (Control)
Number of subjects: 50
Study: 25701273

Group type: EXPERIMENTAL
Intervention: Intervention decision aid including information on overdetection
Number of subjects: 879

Group type: COMPARATOR
Intervention: Control decision aid including information on breast cancer mortality reduction and false positives
Number of subjects: 879
Study: 23265634

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT; Coping Cat)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Medication (sertraline [SRT])
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication
Number of subjects: 438

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Pediatric Anxiety Rating Scale (PARS)
Number of subjects: 438
Study: 21146164

Group type: EXPERIMENTAL
Intervention: Hearing and seeing recordings of a Stravinsky solo clarinet piece performed with three distinct expressive styles: restrained, standard, and exaggerated intention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing and seeing the musical performances.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis of emotional responses.
Number of subjects: 0
Study: 18648184

Group type: EXPERIMENTAL
Intervention: Exercise program consisting of four exercises: expression muscles, tongue, salivary glands, and swallowing, conducted over six months.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intervention group with 20 or more remaining teeth.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intervention group with less than 20 remaining teeth.
Number of subjects: 78
Study: 16534103

Group type: EXPERIMENTAL
Intervention: High Dose Coenzyme Q10 (CoQ10) at preferred dose (either 1800 mg or 2700 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 12743668

Group type: EXPERIMENTAL
Intervention: Adenosine (10 microg x kg(‐1) x min(‐1))
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 608
Study: 10934787

Group type: EXPERIMENTAL
Intervention: Glipizyd tabl. 5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glibenese tabl. 5 mg
Number of subjects: 24
Study: 9887853

Group type: EXPERIMENTAL
Intervention: Five-day standardized family-oriented clinical asthma training program with monthly follow-up for six months (Group 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Same clinical training without follow-up interventions (Group 2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Regular medical treatment according to international guidelines without a training program (Control Group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study: 7816355

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program averaging 4.5 sessions per week for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 33
Study: 3259856

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (500 mg)
Number of subjects: 12
Study: 31623510

Group type: EXPERIMENTAL
Intervention: Production tasks in regions with varying stages of devoicing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perception tasks in regions with varying stages of devoicing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Link between perception and production systems
Number of subjects: 100
Study: 30663529

Group type: EXPERIMENTAL
Intervention: Recalling childhood memories (open-ended or structured)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit childhood manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taking the perspective of a child
Number of subjects: 0

Group type: COMPARATOR
Intervention: Taking the perspective of an adult
Number of subjects: 0
Study: 28774367

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 60
Study: 26083537

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate, 3 mg/kg, administered intravenously 15 minutes before tracheal intubation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo administered 15 minutes before tracheal intubation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 24693629

Group type: EXPERIMENTAL
Intervention: Indirect pulp capping with calcium hydroxide (CH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indirect pulp capping with wax
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both CH and wax
Number of subjects: 30
Study: 21381963

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 42
Study: 18617832

Group type: EXPERIMENTAL
Intervention: Preventive coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 16585434

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 99
Study: 12855628

Group type: EXPERIMENTAL
Intervention: Acupuncture at P6
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo acupuncture at P6
Number of subjects: 80
Study: 11196233

Group type: EXPERIMENTAL
Intervention: Distal Active Concept therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Edgewise therapy (Control)
Number of subjects: 68
Study: 8769679

Group type: EXPERIMENTAL
Intervention: Oral treatment (continuous 17‐beta‐estradiol 2 mg and norethisterone acetate 1 mg per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transdermal therapy (patches delivering continuous 17‐beta‐estradiol 0.05 mg/day with sequential oral medroxyprogesterone acetate 10 mg/day for 12 days/cycle)
Number of subjects: 80
Study: 1605900

Group type: EXPERIMENTAL
Intervention: Estazolam 2 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3884627

Group type: EXPERIMENTAL
Intervention: Glucose plus insulin (1 g + 1.5 U/kg bw X h) before and after ischaemic heart arrest
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group received glucose without insulin
Number of subjects: 36
Study: 30285187

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 5 × 104 cfu/g C. butyricum (CB2) or 1 × 105 cfu/g (CB3)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with C. butyricum
Number of subjects: 960

Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 960
Study: 29492637

Group type: EXPERIMENTAL
Intervention: Fibre supplement (7.5 g of insoluble fibre per serving, twice daily for 2 years)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (0.8 g of insoluble fibre per serving, twice daily for 2 years)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fibre supplement
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 27585414

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil 0.25 μg/kg/min (PRe‐0.25)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil 0.125 μg/kg/min (PRe‐0.125)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol/66% nitrous oxide (PN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol/saline solution (PS)
Number of subjects: 80
Study: 25312556

Group type: EXPERIMENTAL
Intervention: MumsQuit (Internet-based Smoking Cessation Intervention)
Number of subjects: 13
Study: 22393129

Group type: EXPERIMENTAL
Intervention: Irrelevant evidence (5-year survival increased from 68% to 99%)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Relevant evidence (cancer mortality reduced from 2 to 1.6 in 1000 persons)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: General knowledge questions about screening statistics
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Finding more cases of cancer in screened populations
Number of subjects: 412
Study: 20146800

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study: 17663618

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Group interpersonal psychotherapy
Number of subjects: 162
Study: 16118760

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) combined with physiotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Physiotherapy alone (PT group)
Number of subjects: 55
Study: 12704925

Group type: EXPERIMENTAL
Intervention: Vaseline gauze (F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biobrane (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occlusive dressing (O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal mirror-sided skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cutometer (Courage and Khazaka)
Number of subjects: 0
Study: 10400143

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study: 8614572

Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1975277

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg qhs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cimetidine 800 mg qhs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ranitidine 300 mg qhs
Number of subjects: 25